Hoth Therapeutics EBITDA

What does Hoth Therapeutics do? Hoth Therapeutics, Inc. develops new generation therapies for dermatological disorders and related conditions. The company focuses on products like HT-001 for atopic dermatitis, HT-KIT for mast-cell derived cancers, HT-TBI for traumatic brain injury, and HT-ALZ for neuroinflammatory diseases including Alzheimer’s. It also develops HT-003, HT-004, and HT-002 in preclinical stages, alongside a diagnostic device using mobile technology. The firm targets medical professionals and patients seeking advanced treatments for skin conditions, cancer side effects, and neurological disorders. Hoth Therapeutics generates revenue through the development and eventual commercialization of its therapeutic products. It leverages its pipeline of HT-001, HT-KIT, HT-TBI, and HT-ALZ for dermatological, oncological, and neurological markets. The company also capitalizes on third-party assets, such as a lupus treatment, to expand its portfolio. Its primary customers include healthcare providers and patients requiring innovative solutions for unmet medical needs. The company’s business model centers on advancing its therapeutic pipeline to market readiness, with products targeting high-need areas like cancer side effects, neurological diseases, and inflammatory skin conditions. It relies on partnerships for third-party asset development, such as the lupus treatment, to complement its internal research. Hoth Therapeutics aims to monetize its assets through licensing agreements, product sales, and potential future partnerships in the pharmaceutical sector. Hoth Therapeutics is one of the most popular companies on Eulerpool.